Shandong Pharmaceutical Glass Co.Ltd Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next

Shandong Pharmaceutical Glass Co.Ltd (SHSE:600529) shareholders are probably feeling a little disappointed, since its shares fell 9.7% to CN¥28.71 in the week after its latest first-quarter results. The results were mixed; although revenues of CN¥1.3b fell 12% short of analyst estimates, statutory earnings per share (EPS) of CN¥0.33 beat expectations by 18%. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

View our latest analysis for Shandong Pharmaceutical GlassLtd

Taking into account the latest results, the most recent consensus for Shandong Pharmaceutical GlassLtd from seven analysts is for revenues of CN¥5.65b in 2024. If met, it would imply a meaningful 13% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to expand 19% to CN¥1.49. Yet prior to the latest earnings, the analysts had been anticipated revenues of CN¥5.68b and earnings per share (EPS) of CN¥1.49 in 2024. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

The analysts reconfirmed their price target of CN¥34.95, showing that the business is executing well and in line with expectations. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values Shandong Pharmaceutical GlassLtd at CN¥38.01 per share, while the most bearish prices it at CN¥30.60. With such a narrow range of valuations, the analysts apparently share similar views on what they think the business is worth.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Shandong Pharmaceutical GlassLtd's past performance and to peers in the same industry. The analysts are definitely expecting Shandong Pharmaceutical GlassLtd's growth to accelerate, with the forecast 17% annualised growth to the end of 2024 ranking favourably alongside historical growth of 13% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 19% annually. Shandong Pharmaceutical GlassLtd is expected to grow at about the same rate as its industry, so it's not clear that we can draw any conclusions from its growth relative to competitors.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Shandong Pharmaceutical GlassLtd going out to 2026, and you can see them free on our platform here..

We also provide an overview of the Shandong Pharmaceutical GlassLtd Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.